Cargando…
A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters
Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform. In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins. Remodelling the secretory pathway presents an op...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028082/ https://www.ncbi.nlm.nih.gov/pubmed/36959936 http://dx.doi.org/10.3389/fpls.2023.1146234 |
_version_ | 1784909862422970368 |
---|---|
author | Margolin, Emmanuel Schäfer, Georgia Allen, Joel D. Gers, Sophette Woodward, Jeremy Sutherland, Andrew D. Blumenthal, Melissa Meyers, Ann Shaw, Megan L. Preiser, Wolfgang Strasser, Richard Crispin, Max Williamson, Anna-Lise Rybicki, Edward P. Chapman, Ros |
author_facet | Margolin, Emmanuel Schäfer, Georgia Allen, Joel D. Gers, Sophette Woodward, Jeremy Sutherland, Andrew D. Blumenthal, Melissa Meyers, Ann Shaw, Megan L. Preiser, Wolfgang Strasser, Richard Crispin, Max Williamson, Anna-Lise Rybicki, Edward P. Chapman, Ros |
author_sort | Margolin, Emmanuel |
collection | PubMed |
description | Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform. In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins. Remodelling the secretory pathway presents an opportunity to support key post-translational modifications, and to tailor aspects of glycosylation and glycosylation-directed folding. In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus. The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen. The plant-produced protein was decorated with under-processed oligomannose N-glycans and exhibited a site occupancy that was comparable to the equivalent protein produced in mammalian cell culture. Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein. The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen. Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss. Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable. |
format | Online Article Text |
id | pubmed-10028082 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100280822023-03-22 A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters Margolin, Emmanuel Schäfer, Georgia Allen, Joel D. Gers, Sophette Woodward, Jeremy Sutherland, Andrew D. Blumenthal, Melissa Meyers, Ann Shaw, Megan L. Preiser, Wolfgang Strasser, Richard Crispin, Max Williamson, Anna-Lise Rybicki, Edward P. Chapman, Ros Front Plant Sci Plant Science Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform. In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins. Remodelling the secretory pathway presents an opportunity to support key post-translational modifications, and to tailor aspects of glycosylation and glycosylation-directed folding. In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus. The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen. The plant-produced protein was decorated with under-processed oligomannose N-glycans and exhibited a site occupancy that was comparable to the equivalent protein produced in mammalian cell culture. Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein. The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen. Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss. Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable. Frontiers Media S.A. 2023-03-07 /pmc/articles/PMC10028082/ /pubmed/36959936 http://dx.doi.org/10.3389/fpls.2023.1146234 Text en Copyright © 2023 Margolin, Schäfer, Allen, Gers, Woodward, Sutherland, Blumenthal, Meyers, Shaw, Preiser, Strasser, Crispin, Williamson, Rybicki and Chapman https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Plant Science Margolin, Emmanuel Schäfer, Georgia Allen, Joel D. Gers, Sophette Woodward, Jeremy Sutherland, Andrew D. Blumenthal, Melissa Meyers, Ann Shaw, Megan L. Preiser, Wolfgang Strasser, Richard Crispin, Max Williamson, Anna-Lise Rybicki, Edward P. Chapman, Ros A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters |
title | A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters |
title_full | A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters |
title_fullStr | A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters |
title_full_unstemmed | A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters |
title_short | A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters |
title_sort | plant-produced sars-cov-2 spike protein elicits heterologous immunity in hamsters |
topic | Plant Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028082/ https://www.ncbi.nlm.nih.gov/pubmed/36959936 http://dx.doi.org/10.3389/fpls.2023.1146234 |
work_keys_str_mv | AT margolinemmanuel aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT schafergeorgia aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT allenjoeld aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT gerssophette aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT woodwardjeremy aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT sutherlandandrewd aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT blumenthalmelissa aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT meyersann aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT shawmeganl aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT preiserwolfgang aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT strasserrichard aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT crispinmax aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT williamsonannalise aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT rybickiedwardp aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT chapmanros aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT margolinemmanuel plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT schafergeorgia plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT allenjoeld plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT gerssophette plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT woodwardjeremy plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT sutherlandandrewd plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT blumenthalmelissa plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT meyersann plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT shawmeganl plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT preiserwolfgang plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT strasserrichard plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT crispinmax plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT williamsonannalise plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT rybickiedwardp plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters AT chapmanros plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters |